Search Results
Results 601 - 650 of 1822
< 8 9 10 11 12 13 14 15 16 17 18 >
Ichimoto Eiji - - 2010
There is little information about long-term (> 1 year) outcomes after sirolimus-eluting stent (SES) implantation in dialysis patients. Percutaneous coronary intervention (PCI) using SES was performed in 63 dialysis patients with 77 lesions. A control group for comparison was composed of 45 consecutive dialysis patients with 62 lesions who received ...
Jakabcin Jozef J Department of Cardiology, Masaryk Hospital, Ustí nad Labem, Czech Republic 40113, Czech - - 2010
To assess the role of the intravascular ultrasound (IVUS) during implantation of drug-eluting stents (DES) on long-term outcome in patients with complex coronary artery disease and high clinical risk profile with special attention to the development of late stent thrombosis (LST). Two hundred and ten patients were randomly assigned to ...
Lee Michael S - - 2010
This meta-analysis was undertaken to assess the efficacy and safety of drug-eluting stents (DESs) compared to bare metal stents (BMSs) in saphenous vein graft (SVG) interventions. DESs decrease the risk of target vessel revascularization in native coronary arteries compared to BMSs. The ideal treatment strategy in patients with SVG disease ...
Serruys Patrick W - - 2010
OBJECTIVES: The purpose of this study is to compare the 5-year clinical outcomes, safety, and efficacy of sirolimus-eluting stents (SES) in the ARTS II (Arterial Revascularization Therapies Study II) with the outcomes of coronary artery bypass graft (CABG) and bare-metal stenting (BMS) from the ARTS I. BACKGROUND: The long-term outcomes ...
Derksen W J M - - 2010
OBJECTIVES: Restenosis following remote superficial femoral artery endarterectomy (RSFAE) remains a challenging problem. The determinants predicting failure are lacking. This study investigated patient characteristics with predictive value for restenosis during the first year after RSFAE. DESIGN: A prospective cohort study. MATERIALS AND METHODS: A total of 90 patients post-RSFAE were ...
Liistro Francesco - - 2010
OBJECTIVES: The aim of this study was to evaluate the long-term clinical outcome of the efficacy and safety of sirolimus-eluting stents (SES) for in-stent restenosis (ISR) in the TRUE (Tuscany Registry of Unselected In-Stent Restenosis) database. BACKGROUND: The TRUE registry demonstrated that SES in the treatment of bare-metal stent ISR ...
Chen Qingwei - - 2010
The study objectives were to evaluate the safety and effectiveness of PCI in the elderly. The 201 cases with PCI were divided into the younger group (<60-year-old group, 33 cases), the old group (60- to 74-year-old group, 92 cases) and the very old group (75- to 89-year-old group, 76 cases). ...
Takasawa Yosuke - - 2010
BACKGROUND: The best way to treat in-stent restenosis (ISR) after drug-eluting stent (DES) implantation remains unclear. The aim of this study was to evaluate angiographic restenosis and target lesion revascularization (TLR) at 8 months after intervention in patients with DES-ISR, and to identify predictive factors of subsequent TLR after treatment ...
Visconti Gabriella - - 2011
In an attempt to improve the stent's safety, development of bare metal stents (BMS) continues, with new materials and geometry. Chrono™ (CID, Italy) is a thin strut cobalt-chromium (Co-Cr) stent combining the clinical benefits of the bio- and haemo-compatible Carbofilm™ coating. We assessed the safety and efficacy of percutaneous coronary ...
Rathore Sudhir - - 2010
AIMS: This paper studies in-stent restenosis (ISR) after percutaneous coronary intervention (PCI) following bare-metal stent (BMS) and drug-eluting stent (DES) in all consecutive patients between 2004 and 2007 undergoing PCI for ISR lesions at our centre. METHODS AND RESULTS: We compared the clinical presentation, pattern and angiographic outcomes in 838 ...
Syed Asmir I - - 2010
Chronic renal insufficiency (CRI) is associated with an increased incidence of restenosis and stent thrombosis. Drug-eluting stents (DES), when compared to bare metal stents (BMS), reduce the incidence of restenosis in these patients. This study aimed to examine whether there are differences in clinical outcome after implantation of sirolimus-eluting stents ...
Baber Usman - - 2010
BACKGROUND: The optimal combination of anticoagulant and antiplatelet therapy following percutaneous coronary intervention with stenting (PCI-S) among patients requiring oral anticoagulation (OAC) is unknown. OBJECTIVES: We sought to compare the efficacy of a modified dual-antiplatelet regimen (daily aspirin and every other day clopidogrel) to conventional treatment (daily aspirin and daily ...
Schwalm Jon-David R - - 2010
In randomized trials, paclitaxel-eluting stents (PES) are superior to bare metal stents (BMS) in reducing target lesion revascularization (TLR). However, recent reports suggest there may be an increase in late stent thrombosis with long-term follow-up in PES-treated patients. Prospectively collected data from a regional cardiac referral centre were analyzed to ...
Guo Lin - - 2010
Objective:  To evaluate the role of knee arthroscopy in diagnosis and treatment of knee joint synovitis and total joint tuberculosis (TB) of adolescence. Methods:  Forty-one patients with knee TB, aged 7-16 years, were treated using knee arthroscopy from June 2002 to December 2006. Clinical data were reviewed at followed up ...
Bezerra Hiram - - 2010
OBJECTIVE: To examine the 1-year safety and clinical outcomes associated with the post-marketing early unselected use of sirolimus-eluting stents (SES) in the United States. BACKGROUND: The safety and effectiveness of SES has been assessed in selected patients enrolled in pivotal randomized trials. This PMS registry was initiated to examine the ...
Jim Man-Hong - - 2010
The aim of this study was to report the feasibility, short- and medium-term results of percutaneous coronary intervention (PCI) on saphenous vein graft (SVG) chronic total occlusions (CTO) using paclitaxel-eluting stents (PES). In postbypass patients, PCI on SVG CTO, rather than native vessel CTO, is another treatment option. However, the ...
Hilliard Anthony A AA Division of Cardiovascular Diseases, Department of Internal Medicine, Mayo Clinic and Mayo Foundation, Rochester, Minnesota 55905, - - 2010
We sought to determine the characteristics, outcomes, and temporal trends among patients undergoing percutaneous coronary intervention (PCI) for stable coronary artery disease (CAD) from a single-center registry. There is controversy regarding the generalizability of the findings from randomized trials of PCI for stable CAD to daily practice. An important perspective ...
Chamié Daniel D Instituto Dante Pazzanese de Cardiologia, São Paulo, - - 2010
The aim of this study was to evaluate the novel CardioMind Sparrow (CMS) stent (CardioMind, Inc., Sunnyvale, California) against the Multi-Link Pixel (MLP) stent (Guidant Corp., Santa Clara, California) for small vessel percutaneous coronary intervention (PCI). The CMS consists of a guidewire-based, self-expandable, ultra-thin nitinol stent with smaller profile and ...
Hara Masahiko M Division of Cardiology, Osaka Rosai Hospital, Sakai, Osaka, Japan. - - 2010
The purpose of this study is to compare the neointimal formational pattern and incidence of thrombus formation among sirolimus-eluting (SES), paclitaxel-eluting (PES), and bare-metal stents (BMS) with coronary angioscopy. Neointimal formation and incidence of mural thrombus are different with the type of stent. One hundred successive patients who received 43 ...
Abualsaud Ali O AO Division of Cardiology, Royal Victoria Hospital/McGill University Health Centre, Montreal, Quebec, - - 2010
Thrombosis of a drug-eluting stent (DES) is a catastrophic complication. The risk of stent thrombosis (ST) is increased in the perioperative setting and is strongly associated with the cessation of antiplatelet therapy. This article reviews the perioperative management of patients with DES with a clinical focus on the perioperative use ...
Shirai Shinichi S Division of Cardiology, Kokura Memorial Hospital, Kokura, - - 2010
Our aim was to study the relationships between total stent length (TSL) and long-term clinical outcomes after sirolimus-eluting stent (SES) implantation. SES compared with bare-metal stent use for long lesion treatment is associated with reduced restenosis rates. Three-year follow-up data were available for 10,773 patients (14,651 lesions) that had been ...
Onuma Yoshinobu - - 2010
To investigate the clinical impact of the following observations in the randomized SPIRIT II and III trials: an incremental increase in in-stent neointima between 1 and 2 years with the everolimus-eluting stent (EES) but not with the paclitaxel-eluting stent (PES) in SPIRIT II; a tendency of lower stent thrombosis in ...
Jennings Douglas L - - 2010
The purpose of this study is to evaluate the effect of adding cilostazol to dual antiplatelet therapy (aspirin and thienopyridine) on rates of restenosis after coronary artery stenting. A meta-analysis is conducted of randomized, controlled trials comparing 3 drug regimens (cilostazol, thienopyridine, aspirin [triple therapy]) with dual antiplatelet therapy to ...
Syed Asmir I - - 2010
Background: Chronic renal insufficiency (CRI) is associated with an increased incidence of restenosis and stent thrombosis. Drug-eluting stents (DES), when compared to bare metal stents (BMS), reduce the incidence of restenosis in these patients. This study aimed to examine whether there are differences in clinical outcome after implantation of sirolimus-eluting ...
Jim Man-Hong - - 2010
Objectives:The aim of this study was to report the feasibility, short- and medium-term results of percutaneous coronary intervention (PCI) on saphenous vein graft (SVG) chronic total occlusions (CTO) using paclitaxel-eluting stents (PES). Background:In postbypass patients, PCI on SVG CTO, rather than native vessel CTO, is another treatment option. However, the ...
Biondi-Zoccai Giuseppe G L - - 2010
BACKGROUND: Most cardiologists performing percutaneous coronary intervention (PCI) with drug-eluting stents (DES) for unprotected left main disease (ULM) mandate mid-term angiographic follow-up, yet there are few data supporting this approach. We aimed to retrospectively compare the outcome of patients with ULM treated with DES according to their follow-up management strategy. ...
Kotowycz Mark A - - 2010
BACKGROUND: Patients with ST-segment elevation myocardial infarction (STEMI) have traditionally been hospitalized for 5 to 7 days to monitor for serious complications such as heart failure, arrhythmias, reinfarction, and death. The Zwolle Primary Percutaneous Coronary Intervention (PCI) Index is an externally validated risk score that has been used to identify ...
Takeuchi Ichiro - - 2010
A drug eluting stent is often used for high-risk patients with complications such as diabetes mellitus (DM) and hemodialysis (HD), however the factors to predict restenosis after paclitaxel-eluting stent (PES) placement have not been reported to date. Between May 2007 and August 2009, 165 consecutive patients (231 stents) received PES ...
Goswami Nilesh J - - 2010
OBJECTIVES: This study was designed to compare long-term clinical outcomes of drug-eluting stents (DES) versus bare metal stents (BMS) in patients with saphenous vein graft (SVG) disease in the "real world." BACKGROUND: The safety and efficacy of DES versus BMS in SVG remains uncertain due to contradictory reports of either ...
Yock Cynthia A - - 2010
BACKGROUND: The goal of this study was to assess the rate and anatomical targets of repeat revascularization procedures in routine clinical practice after either bare-metal stent (BMS) or drug-eluting stent (DES) implantation. Randomized trials provide a reference standard for comparing outcomes after BMS or DES, but the rates of repeat ...
Tresukosol Damras - - 2010
OBJECTIVE: Percutaneous coronary intervention (PCI) has been widely used to treat obstructive coronary artery disease. With the advent of drug-eluting stent (DES) in real world registry was proved as promising therapy. The limitation of the use of DES is the limited health care expenditure. We propose the use of Chinese ...
Ari Hasan - - 2010
The aim of this study is to investigate if serum asymmetric dimethylarginine (ADMA) levels can predict restenosis and major adverse cardiac events (MACE) in patients who undergo percutaneous coronary interventions. The most important cause of restenosis following percutaneous coronary intervention is neointimal hyperplasia. Nitric oxide (NO) prevents the neointimal hyperplasia ...
Watanabe Tomoyuki - - 2010
A 73-year-old male in a persistent vegetative state underwent percutaneous coronary intervention (PCI) for unstable angina with multiple-vessel stenosis. The maximum dose pharmaceutical therapy was ineffective in controlling his symptoms. The goal of the procedure was to alleviate the patient's severe chest pain and vomiting with minimal invasion and risk. ...
Rajoria Kshipra - - 2010
The objective of the present research was to study the efficacy of Laksha Guggulu, Snehana, Swedana & Traction in the management of Osteoarthritis (Knee joint). For the present work, 30 clinically diagnosed patients were selected and randomly divided into three groups. Group A treated with Laksha Guggulu orally, Group B ...
Costa J Ribamar JR Jr Instituto de Ensino e Pesquisa, Hospital do Coração, São Paulo, Brazil. - - 2010
Our aim was to access the incidence of late major adverse cardiac events (MACE) and stent thrombosis (ST) in nonselected, complex patients followed for a period >/=4 years. Despite the efficacy of drug-eluting stents (DES) in reducing repeated target lesion revascularization, concerns regarding the occurrence of late and very late ...
Feldman Dmitriy N - - 2010
Current guidelines recommend pretreatment with a loading dose of clopidogrel before percutaneous coronary intervention (PCI) to reduce the incidence of periprocedural myocardial infarctions in patients undergoing PCI. However, because of concerns about postoperative bleeding, clopidogrel loading is frequently administered either immediately before or after PCI. Using the 2004/2005 Cornell Angioplasty ...
Sukhija Rishi - - 2010
No data are available comparing the long-term outcome of sirolimus-eluting stents (SESs) versus paclitaxel-eluting stents (PESs) in patients with moderate to severe renal insufficiency. The incidence of major adverse cardiac events (MACE), including death, myocardial infarction, and target vessel revascularization, during long-term follow-up were studied in patients with a glomerular ...
Lee Seung-Whan - - 2010
Although cilostazol has decreased restenosis and target lesion revascularization (TLR) after drug-eluting stent implantation, it is not known if this effect is durable at 2 years. We analyzed 2 randomized studies (Drug-Eluting stenting followed by Cilostazol treatment reduces LAte REstenosis in patients with DIABETES mellitus and Drug-Eluting Stenting Followed by ...
Est?vez-Loureiro Rodrigo - - 2009
INTRODUCTION AND OBJECTIVES: At present, little information is available on returning patients with ST-elevation myocardial infarction (STEMI) to their originating centers after transfer for primary percutaneous coronary intervention (PPCI). The objective of this study was to evaluate the safety and feasibility of the early return of these patients to their ...
Quadros Alexandre S - - 2009
OBJECTIVE: Our aim was to validate a risk score for new target vessel revascularization (TVR) after bare-metal stent (BMS) implantation. METHODS: The risk score was developed in a cohort of patients previously treated with BMS at our institution. This risk score ranges from 0 to 5 points, according to the ...
Darwazah A K - - 2009
AIM: The incidence of patients subjected to emergency coronary artery bypass graft (CABG) after percutaneous coronary intervention (PCI) is decreasing due to improvement of PCI technique and device technology. The aim of our study is to evaluate cases subjected to emergency CABG after complicated PCI to determine incidence, indications and ...
Hong Young Joon - - 2009
BACKGROUND: The N-terminal pro-B-type natriuretic peptide (NT-pro-BNP) is a sensitive indicator of hemodynamic stress and its increased level is associated with higher mortality in acute coronary syndrome (ACS) patients. Virtual histology-intravascular ultrasound (VH-IVUS) can provide quantitative information on plaque components. METHODS: We measured preprocedural serum NT-pro-BNP levels in 156 ACS ...
Shen Zhu Jun - - 2009
BACKGROUND: The use of drug eluting stents (DES) in patients with a successfully recanalized chronic total occlusion (CTO) has been associated with a significant decrease in the need for repeat revascularization, and a favorable short-term clinical outcome when compared with the use of bare metal stents (BMS). Our group, however, ...
Moussa Issam D - - 2009
Drug-eluting stents (DES) have several advantages over bare-metal stents (BMS), including significantly lower target vessel revascularization. However, DES is associated with a higher incidence of late stent thrombosis (ST). Although late ST after DES placement is uncommon (approximately 0.4-0.6%/year), it is catastrophic clinical consequences make it a concern. Dual antiplatelet ...
Bagur Rodrigo - - 2009
No data are available on the long term efficacy of abciximab bolus-only with aspirin and clopidogrel pretreatment and systematic coronary stenting. Our objective was to evaluate the 3-year clinical outcomes in the EASY trial. After a bolus of abciximab (0.25 mg/kg) and uncomplicated transradial coronary stenting, 1,005 patients were randomized ...
Meredith Ian T IT Monash Medical Centre and Monash University, 246 Clayton Road, Clayton, Melbourne, Australia. - - 2009
To evaluate the 5-year clinical outcomes of patients treated with the Endeavor zotarolimus-eluting stent (ZES) in the ENDEAVOR I first-in-human study. ENDEAVOR I was a prospective, nonrandomized, multicenter study of the Endeavor ZES in 100 consecutive patients with symptomatic coronary artery disease (CAD) due to de novo, stenotic lesions in ...
Ellis Stephen G SG Cleveland Clinic, Department of Cardiology, Cleveland, Ohio 44195, USA. - - 2009
The pivotal TAXUS IV (TAXUS IV-SR: Treatment of De Novo Coronary Disease Using a Single Paclitaxel-Eluting Stent) trial evaluated the long-term safety and effectiveness of the paclitaxel-eluting stent (PES) compared with an otherwise identical bare-metal stent (BMS) in a relatively uncomplicated population of patients with a single de novo lesion ...
De Felice Francesco F UO Cardiologia Interventistica, Azienda Ospedaliera S. Camillo Forlanini, Rome, Italy. - - 2009
The aim of this study was to evaluate whether percutaneous coronary intervention (PCI) with drug-eluting stent (DES) reduces major adverse cardiac events (MACE) in patients with chronic coronary total occlusions (CTO) compared with bare-metal stent (BMS) during 3-year follow-up. The long-term prognosis of patients with CTO treated with PCI and ...
Kandzari David E DE Division of Cardiovascular Disease, Scripps Clinic, La Jolla, California 92037, USA. - - 2009
Uncertainty regarding the appropriate duration of dual antiplatelet therapy (DAPT) with aspirin and a thienopyridine challenges every clinician involved in the care of patients considered for or treated with drug-eluting stents (DES). Despite guideline recommendations for extended (> or =12 months) DAPT following percutaneous coronary revascularization with DES, few data ...
Lairez Olivier - - 2009
Previous studies have reported circadian variation in the rate of post-percutaneous coronary intervention (PCI) complications and mortality. To assess whether in-hospital outcomes during the first 48h after admission are related to the time or the day when PCI is performed. Emergency PCIs (2266 total; 1396 during regular hours and 870 ...
< 8 9 10 11 12 13 14 15 16 17 18 >